169 related articles for article (PubMed ID: 21889193)
21. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population.
Le T
Eur J Surg Oncol; 2001 Apr; 27(3):282-5. PubMed ID: 11373106
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
Sutton G; Kauderer J; Carson LF; Lentz SS; Whitney CW; Gallion H;
Gynecol Oncol; 2005 Mar; 96(3):630-4. PubMed ID: 15721404
[TBL] [Abstract][Full Text] [Related]
23. Clinical features and outcomes of uterine and ovarian carcinosarcoma.
Jonson AL; Bliss RL; Truskinovsky A; Judson P; Argenta P; Carson L; Dusenbery K; Downs LS
Gynecol Oncol; 2006 Mar; 100(3):561-4. PubMed ID: 16271748
[TBL] [Abstract][Full Text] [Related]
24. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma.
Chi DS; Mychalczak B; Saigo PE; Rescigno J; Brown CL
Gynecol Oncol; 1997 Jun; 65(3):493-8. PubMed ID: 9190981
[TBL] [Abstract][Full Text] [Related]
25. Stage III uterine carcinosarcoma: 2009 International Federation of Gynecology and Obstetrics Staging System and Prognostic Determinants.
Garg G; Kruger M; Christensen C; Deppe G; Toy EP
Int J Gynecol Cancer; 2011 Dec; 21(9):1606-12. PubMed ID: 21720252
[TBL] [Abstract][Full Text] [Related]
26. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study.
Sartori E; Bazzurini L; Gadducci A; Landoni F; Lissoni A; Maggino T; Zola P; La Face B
Gynecol Oncol; 1997 Oct; 67(1):70-5. PubMed ID: 9345359
[TBL] [Abstract][Full Text] [Related]
27. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy.
Nelson G; Randall M; Sutton G; Moore D; Hurteau J; Look K
Gynecol Oncol; 1999 Nov; 75(2):211-4. PubMed ID: 10525373
[TBL] [Abstract][Full Text] [Related]
28. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Gynecol Oncol; 2016 Jun; 141(3):447-453. PubMed ID: 27072806
[TBL] [Abstract][Full Text] [Related]
29. Prognostic determinants in patients with uterine and ovarian carcinosarcoma.
Rauh-Hain JA; Shoni M; Schorge JO; Goodman A; Horowitz NS; del Carmen MG
J Reprod Med; 2013; 58(7-8):297-304. PubMed ID: 23947079
[TBL] [Abstract][Full Text] [Related]
30. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.
Callister M; Ramondetta LM; Jhingran A; Burke TW; Eifel PJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):786-96. PubMed ID: 14967435
[TBL] [Abstract][Full Text] [Related]
31. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
Vaidya AP; Horowitz NS; Oliva E; Halpern EF; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):684-7. PubMed ID: 16797683
[TBL] [Abstract][Full Text] [Related]
32. Impact of adjuvant pelvic radiotherapy in stage I uterine sarcoma.
Magnuson WJ; Petereit DG; Anderson BM; Geye HM; Bradley KA
Anticancer Res; 2015 Jan; 35(1):365-70. PubMed ID: 25550573
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathologic characteristics and prognosis factors of uterine sarcomas in central Tunisia].
Khlifi A; Fathallah K; Zbidi C; Hidar S; Bibi M; Khairi H
Bull Cancer; 2014; 101(7-8):669-80. PubMed ID: 25091649
[TBL] [Abstract][Full Text] [Related]
34. [Comparison between FIGO old and new staging criteria of endometrial carcinoma].
Jobo T; Ohkawara S; Kuramoto H; Hata H; Shimoda T; Tsunoda S; Tsujii A
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jan; 43(1):31-7. PubMed ID: 1997614
[TBL] [Abstract][Full Text] [Related]
35. The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoma of uterus.
Park JY; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
Ann Surg Oncol; 2010 Mar; 17(3):861-8. PubMed ID: 19921530
[TBL] [Abstract][Full Text] [Related]
36. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
37. SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988-1994.
Cornelison TL; Trimble EL; Kosary CL
Gynecol Oncol; 1999 Sep; 74(3):350-5. PubMed ID: 10479492
[TBL] [Abstract][Full Text] [Related]
38. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
39. A suggested modification to FIGO stage III vulvar cancer.
Rouzier R; Preti M; Sideri M; Paniel BJ; Jones RW
Gynecol Oncol; 2008 Jul; 110(1):83-6. PubMed ID: 18436291
[TBL] [Abstract][Full Text] [Related]
40. Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma.
Chang SJ; Kim WY; Yoon JH; Yoo SC; Chang KH; Ryu HS
Acta Obstet Gynecol Scand; 2008; 87(12):1361-9. PubMed ID: 18951214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
